Brii Biosciences Limited
HKEX:2137.HK
1.09 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0.617 | 51.626 | 92.542 | 82.218 | 20.196 |
| Cost of Revenue
| -55.274 | 0 | 0 | 0 | 0 |
| Gross Profit
| 55.891 | 51.626 | 92.542 | 82.218 | 20.196 |
| Gross Profit Ratio
| 90.585 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 402.705 | 440.634 | 494.615 | 875.795 | 83.785 |
| General & Administrative Expenses
| 55.685 | 53.465 | 79.307 | 49.838 | 22.548 |
| Selling & Marketing Expenses
| 1.419 | 26.861 | 0 | 0 | 0 |
| SG&A
| 57.104 | 80.326 | 79.307 | 49.838 | 22.548 |
| Other Expenses
| 0.431 | 44.854 | 68.692 | -13.749 | 20.59 |
| Operating Expenses
| 545.349 | 565.814 | 642.614 | 911.884 | 126.923 |
| Operating Income
| -544.732 | -520.616 | -4,234.704 | -1,266.823 | -525.213 |
| Operating Income Ratio
| -882.872 | -10.084 | -45.76 | -15.408 | -26.006 |
| Total Other Income Expenses Net
| 360.362 | 30.835 | 43.62 | -16.687 | 4.185 |
| Income Before Tax
| -184.37 | -489.781 | -4,191.084 | -1,283.51 | -521.028 |
| Income Before Tax Ratio
| -298.817 | -9.487 | -45.288 | -15.611 | -25.799 |
| Income Tax Expense
| -9.541 | -37.155 | -70.855 | -77.223 | -4.185 |
| Net Income
| -174.829 | -452.626 | -4,120.229 | -1,206.287 | -516.843 |
| Net Income Ratio
| -283.353 | -8.767 | -44.523 | -14.672 | -25.591 |
| EPS
| -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| EPS Diluted
| -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| EBITDA
| -430.827 | -503.584 | -4,217.442 | -1,252.614 | -517.72 |
| EBITDA Ratio
| -698.261 | -9.754 | -45.573 | -15.235 | -25.635 |